Practical Neurology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Practical Neurology 2007;7:234-244; doi:10.1136/jnnp.2007.124263
Copyright © 2007 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joseph, F G
Right arrow Articles by Scolding, N J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joseph, F G
Right arrow Articles by Scolding, N J
Topic Collections
Right arrowRelated Article

Reviews

Sarcoidosis of the nervous system

F G Joseph, Specialist Registrar in Neurology, N J Scolding, Professor of Clinical Neurosciences

Department of Neurology, Institute of Clinical Neurosciences, University of Bristol, Bristol, UKProfessor N J Scolding, Department of Neurology, Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, Bristol BS16 1LE, UK; N.J.Scolding{at}bristol.ac.uk

EXTRACT

Although sarcoidosis is rarely confined to the nervous system, any neurological features that do occur frequently happen early in the course of the disease. The most common neurological presentation is with cranial neuropathies, but seizures, chronic meningitis and the effects of mass lesions are also frequent. The diagnostic process should first confirm nervous system involvement and then provide supportive evidence for the underlying disease; in the absence of any positive tissue biopsy, the most useful diagnostic tests are gadolinium enhanced MRI of the brain and CSF analysis, although both are non-specific. The mainstay of treatment is corticosteroids, but these often have to be combined with other immunosuppressants such as methotrexate, hydroxychloroquine or cyclophosphamide. There is increasing evidence that infliximab is a safe treatment with good steroid sparing capacity. ...

[PDF of this article]

Related Article

EDITOR’S CHOICE
Charles Warlow
Practical Neurology 2007 7: 209. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
PNHome page
S H Wong, M Boggild, T P Enevoldson, and N A Fletcher
Myelopathy but normal MRI: where next?
Practical Neurology, April 1, 2008; 8(2): 90 - 102.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd.